We report a Japanese man who presented with multiple cranial nerve palsies with hepatitis B virus-related multiple hepatocellular carcinoma (HCC). He presented with right III, IV, VI, IX, X, and XII cranial nerve palsies. Metastases involving the clivus and the right occipital bone from HCC were diagnosed by the findings of magnetic resonance imaging of the head, cerebral angiography, and 2-deoxy-2-[
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death in Japan, and it frequently metastasizes to the lung, regional lymph nodes, and the skeletal system (1) . In the skeletal system, metastasis occurs commonly in the spine, ribs, pelvis, and long bones, but skull metastasis has been rarely reported (2, 3) . When extrahepatic metastasis from HCC occurred, the prognosis was reported to be poor (1) . We describe a patient presenting with multiple cranial nerve palsies with skull metastases from HCC, who was successfully treated with radiotherapy.
Case Report
A 65-year-old Japanese man had been treated for chronic hepatitis B virus infection for 12 years, and multiple HCC in S3, S5, and S7 with cirrhosis were identified, and treated with transcatheter embolization (TAE) seven months before the onset of neurological symptoms. He presented with difficulty of speech and swallowing, and right occipitalgia for one month, followed by double vision. Neurological examination revealed restriction of right eyeball movement and right-side soft palatal movement, diplopia, dysarthria, dysphagia, hoarseness, and deviation of the tongue to the right side, which suggested right VI, IX, X, and XII cranial nerve palsies.
Laboratory studies on admission revealed the following abnormal values: platelets 7.3×10 4 /μL, aspartate aminotransferase 54 IU/L (normal limit <40), alanine aminotransferase 54 IU/L (normal limit <45), lactate dehydrogenase 234 IU/L (normal limit <220), alkaline phosphatase 525 IU/L (normal limit <360), alfa-fetoprotein (AFP) 14,000 ng/mL (normal limit <10), and protein induced by vitamin K absence (PIVKA-II) 7,688 MAU/mL (normal limit <39). Examination of cerebrospinal fluid showed no remarkable findings, and the cytology was negative. Magnetic resonance imaging (MRI) of the head revealed a mass involving the clivus with isointensity on T1-weighted images (T1WI) (Fig. 1A) , which was intermediately enhanced on contrast-enhanced T1 WI (Fig. 1B, 1C ). Computed tomography (CT) of the head showed osteolytic change of the clivus, and abdominal CT showed two HCC in the liver (S2 and S5). 
2-deoxy-2-[ 18 F]fluoro-D-glucose positron emission tomography/computed tomography (FDG-PET/ CT) showed increased uptake in the clivus (E) (white arrowheads). Radiotherapy was delivered to the skull base, illustrated as a gray field (F) (black arrowheads). The dose distribution of radiotherapy to the skull base is illustrated (G).
raphy confirmed an abnormal tumor stain supplied from the external carotid artery via the ascending pharyngeal artery (Fig. 1D ). After the recurrence of multiple HCC had been treated with TAE, 2-deoxy-2-[
18 F]fluoro-D-glucose positron emission tomography/CT (FDG-PET/CT) showed an increased uptake in the clivus without any other site of abnormal uptake (Fig. 1E) .
Skull base metastasis from HCC was diagnosed on the basis of these findings. About 50 days after the initial symptoms, radiotherapy was delivered using laterally opposed 10 MV X-rays to the skull base, which is shown as a gray field in Fig. 1F , with a total dose of 50 Gy in 2.5 Gy daily fractionated doses for one month. The dose distribution of radiotherapy to the skull base is illustrated in Fig. 1G . His oral intake was extremely poor, and he was treated with nasogastric tube feeding, and then enteral feeding by percutaneous endoscopic gastrostomy. Right ptosis and fixation of his right eyeball movement developed two months after onset of the first neurological manifestations, which suggested right III and IV cranial nerve palsies. After radiotherapy, the values of tumor markers markedly decreased (AFP 591 IU/ L; PIVKA-II 965 MAU/mL).
Five months after the onset of the initial neurological manifestations, right occipital bone metastasis was identified with markedly elevated levels of tumor markers (AFP 1,214 IU/L; PIVKA-II 9,963 MAU/mL) ( Fig. 2A) . Radiotherapy was delivered to the gray field in Fig. 2B with 10 MV Xrays to a total dose of 50 Gy in 25 fractions for five weeks.
Dysarthria and dysphasia gradually improved six months after the onset of neurological symptoms, and oral intake became possible. Improvement of right ptosis and horizontal eyeball movement were identified eight months after the initial symptoms with a decrease in tumor markers (AFP 224 IU/L; PIVKA-II 241 MAU/mL). The lesion in the clivus was heterogeneously enhanced, and the right occipital lesion disappeared on contrast-enhanced T1WI of MRI (Fig. 2C) ; FDG-PET/CT revealed no abnormal uptake in the head (Fig. 2D ), but it was unknown whether or not abnormal uptake in the right occipital bone was improved by the second radiotherapy because FDG-PET/CT was not performed before the second radiotherapy. At fifteen months after the initial symptoms, he demonstrated no adverse effects of radiotherapy.
Discussion
Skull metastasis frequently occurs in lung and breast cancers. In the previous report, bone metastasis from HCC was 4-20% (1); however, the incidence of skull metastasis from HCC has been reported to be 0.4-1.6% (4). Only 25 cases of skull base metastasis of HCC have been reported (3). Cranial nerve deficits were found in 41% of cases of skull metastasis (4) , and in 96% of cases of skull base metastasis (3). Survival time of the 42 patients with skull metastasis from HCC ranged from 6 days to 108 months (mean 8.9 months) (4), but the 17 patients with skull base metastasis survived from 51 days to 12 months (mean 5.4 months) (3). The main causes of death with skull metastasis were linked to the primary disease (4).
Skull metastases from HCC have been reported to be treated with radiotherapy, chemotherapy, and surgery, including TAE or ethanol injection before surgery (3) (4) (5) (6) (7) (8) .
It was reported that radiotherapy for bone metastasis of HCC was delivered with a total dose 12.5-66 Gy, and the median survival time from the start of radiotherapy ranged from 5 to 7.4 months (9-11). The median survival time of patients with bone metastasis in the untreated group was reported to be 2.9 months (12), and it was considered that radiotherapy might slightly prolong the survival time with bone metastasis from HCC. Bone metastases frequently occur in breast, prostate, thyroid, kidney, and lung cancer (13) , and the median survival time after bone metastasis from breast, prostate, and lung cancer are reported to be 16.4 months, 9.5 months, and 3.2 months, respectively (14). There have been a few reports about whether local radiotherapy could prolong the survival time in cases of bone metastasis of various cancers, and pain relief was obtained in 80% of breast cancer, 78% of prostate cancer, 73% of HCC, 62% of lung cancer, and 48% of renal carcinoma cases (10, 15, 16) .
Radiotherapy may prolong the survival time of patients with intracranial metastasis from HCC (17); however, the patient with skull base metastasis, who was treated with local radiotherapy (30 or 45 Gy), died within twelve months after the onset of neurological manifestations (3, 8, 18) . One patient with skull base metastasis from HCC, who was treated with gamma knife radiosurgery (marginal dose 25 Gy), survived over 24 months in spite of tumor enlargement (5) . In the present case, a total dose of 50 Gy was delivered to the skull base and occipital bone for tumor regression in addition to pain relief because it was reported that a dose-response relationship was identified in local radiotherapy for HCC (19) , and the tolerance dose 5/5 of entire brainstem is 50 Gy (20) . In the skull base metastasis of our patient, radiotherapy was delivered at a slightly higher dose/ fraction to block the progression of multiple cranial nerve palsies as soon as possible.
Metastasis from HCC to separate parts of the skull without metastasis to sites other than the skull, as found in our patient, is considered to be extremely rare, and metastases to both the skull base and other skull parts from HCC have not been found to our knowledge. Clivus metastases are also rare, and only 34 cases have been reported; these metastases frequently occurred in prostate cancer (nine cases, 26.4%), thyroid cancer (four cases, 11.7%), and HCC (four cases) (21) . Furthermore, it was also rare that the present case could be successfully treated with radiotherapy in spite of skull base metastasis, which is commonly associated with a poor prognosis. It was considered that the prolonged survival time with improved neurological manifestation in our case was associated with good control of the primary lesions and no metastasis to any other site.
In the present case, although histological examination was not performed, the diagnosis was considered to be skull metastases from HCC from the following findings: extremely elevated levels of tumor markers, and the findings of some imaging modalities. When skull metastasis from HCC is diagnosed, radiotherapy may be an option for the metastatic lesions. Although our patient presented with no adverse effects of radiotherapy at the last follow-up, a system using intensity-modulated radiation therapy should be established to reduce the radiation dose to the brainstem for skull base metastasis.
